Edward Fox
Round Rock, TXNPI 1871528042
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $331,879 of the $516,831 with a category attached, or 64.2%. 49 manufacturers reported payments, led by Biogen at 24.8% of the total. Reporting peaked in 2022 at $150,516 and has fallen 98.3% since, to $2,608 in 2025.
Across 908 payments — averaging $569.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$128K
- Bristol Myers Squibb$63K
- E.r. Squibb & Sons, L.L.C.$60K
- Genentech USA, Inc.$52K
- Novartis$48K
- EMD Serono, Inc.$39K
- plus $125K from 43 others
Across 313 payments — averaging $20,085 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.1M
- Biogen$393K
- F. Hoffmann-la Roche AG$378K
- Genentech, Inc.$347K
- AbbVie$273K
- Sanofi$195K
- plus $600K from 12 others
What the payments were for
- Consulting fees$119,80323%
- Speaking & faculty fees$331,87964%
- Travel & lodging$28,5796%
- Food & beverage$18,9284%
- Education$17,6423%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 16 | $153,487 |
| Plegridy PenPeginterferon Beta-1a | 11 | $90,924 |
| Glatiramer Acetate | 16 | $43,918 |
| Teriflunomide | 13 | $6,369 |
| Baclofen | 71 | $2,660 |
| Dimethyl Fumarate | 15 | $1,687 |
| Gabapentin | 54 | $1,498 |
| Carbamazepine | 14 | $1,190 |
| Tizanidine Hcl | 35 | $749 |
| Duloxetine Hcl | 22 | $577 |
| Levetiracetam | 12 | $532 |
| Sertraline Hcl | 17 | $101 |
| Escitalopram Oxalate | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.